Timothy J Wilkin

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine
    Timothy Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    HIV Clin Trials 14:75-9. 2013
  2. ncbi A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    J Infect Dis 206:534-42. 2012
  3. ncbi Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men
    Timothy Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, Montefiore Medical Center, New York, New York, USA
    J Infect Dis 202:1246-53. 2010
  4. ncbi The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    HIV Clin Trials 11:351-8. 2010
  5. ncbi Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, New York, USA
    J Infect Dis 199:866-71. 2009
  6. ncbi When to start antiretroviral therapy?
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 47:1580-6. 2008
  7. ncbi Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity
    Timothy J Wilkin
    Division of Infectious Disease, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 52:925-8. 2011
  8. ncbi CCR5 antagonism in HIV infection: current concepts and future opportunities
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10065, USA
    Annu Rev Med 63:81-93. 2012
  9. ncbi HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Clin Infect Dis 44:591-5. 2007
  10. ncbi Antiretroviral therapy: when and what to start-- an American perspective
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr HIV/AIDS Rep 1:59-67. 2004

Research Grants

  1. Anal Dysplasia in HIV+ and HIV- men
    Timothy Wilkin; Fiscal Year: 2006

Detail Information

Publications22

  1. ncbi High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine
    Timothy Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    HIV Clin Trials 14:75-9. 2013
    ..High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer...
  2. ncbi A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    J Infect Dis 206:534-42. 2012
    ..Despite viral suppression, antiretroviral therapy (ART) does not restore CD4(+) T-cell counts in many patients infected with human immunodeficiency virus type 1 (HIV-1)...
  3. ncbi Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men
    Timothy Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, Montefiore Medical Center, New York, New York, USA
    J Infect Dis 202:1246-53. 2010
    ..Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types...
  4. ncbi The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    HIV Clin Trials 11:351-8. 2010
    ..This observation supports further evaluation of CCR5 antagonists in patients with discordant immunologic and virologic responses to ART...
  5. ncbi Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, New York, USA
    J Infect Dis 199:866-71. 2009
    ..Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits, low pill burden, once-daily dosage, and safety...
  6. ncbi When to start antiretroviral therapy?
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 47:1580-6. 2008
    ..Additional cohort and clinical trials data are needed...
  7. ncbi Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity
    Timothy J Wilkin
    Division of Infectious Disease, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 52:925-8. 2011
    ..Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts...
  8. ncbi CCR5 antagonism in HIV infection: current concepts and future opportunities
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10065, USA
    Annu Rev Med 63:81-93. 2012
    ..In addition to virologic effects, CCR5 antagonists are under investigation for immune-modulating effects and for HIV-1 prevention. Ongoing research will further elucidate the role of CCR5 antagonists in combating HIV disease...
  9. ncbi HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Clin Infect Dis 44:591-5. 2007
    ..Chemokine coreceptor use impacts both the natural history of human immunodeficiency virus type 1 (HIV-1) disease and the potential use of a new class of antiretroviral agents, the CCR5 inhibitors...
  10. ncbi Antiretroviral therapy: when and what to start-- an American perspective
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr HIV/AIDS Rep 1:59-67. 2004
    ....
  11. ncbi Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy
    T J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10011, USA
    J Infect Dis 190:1685-91. 2004
    ....
  12. ncbi Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients
    Timothy J Wilkin
    Division of Infectious Diseases Weill Cornell Medical College, New York, NY, USA
    J Acquir Immune Defic Syndr 54:470-6. 2010
    ..Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity...
  13. ncbi Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York, NY, USA
    J Infect Dis 196:304-12. 2007
    ..Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study...
  14. ncbi Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy
    Timothy J Wilkin
    Weill Medical College of Cornell University, New York, NY, USA
    Top HIV Med 16:31-60. 2008
    ....
  15. ncbi Advances in antiretroviral therapy
    Timothy J Wilkin
    Weill Medical College of Cornell University, New York, NY, USA
    Top HIV Med 17:68-88. 2009
    ....
  16. ncbi Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10021, USA
    Clin Infect Dis 45:1062-70. 2007
    ..We projected the long-term outcomes of this treatment simplification strategy to inform the design of a proposed multicenter, randomized clinical trial...
  17. ncbi Advances in antiretroviral therapy
    Barbara Taylor
    Division of Infectious Diseases, University of Texas, San Antonio, TX, USA
    Top Antivir Med 19:69-97. 2011
    ..Prevention of mother-to-child transmission continued to be an important part of the conference...
  18. ncbi Advances in antiretroviral therapy
    Joyce Jones
    Columbia University Medical Center, New York, NY, USA
    Top HIV Med 15:48-82. 2007
    ..Research in antiretroviral therapy remains dynamic and advances in the field continue to improve our ability to maintain long-term control of HIV-1 replication in infected persons...
  19. ncbi Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA
    Magdalena E Sobieszczyk
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    Top HIV Med 12:9-29. 2004
    ..This reviews summarizes new information relevant to clinicians and clinical researchers...
  20. ncbi Advances in antiretroviral therapy
    Susan Olender
    Columbia University Medical Center, New York, NY, USA
    Top Antivir Med 20:61-86. 2012
    ..In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented...
  21. ncbi Advances in antiretroviral therapy
    Timothy J Wilkin
    Weill Cornell Medical College, New York, NY, USA
    Top HIV Med 18:66-92. 2010
    ..Several interesting smaller studies were focused on HIV-1 pathogenesis and persistent viremia...
  22. ncbi Advances in antiretroviral therapy
    Mary A Albrecht
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Top HIV Med 11:97-127. 2003

Research Grants1

  1. Anal Dysplasia in HIV+ and HIV- men
    Timothy Wilkin; Fiscal Year: 2006
    ..This study will help provide important new information on which groups of HIV+ men may benefit from screening and how HAART may modify this risk. ..